PALO ALTO, Calif., August 30, 2026
BridgeBio Pharma, Inc. presented new data from the Phase 3 ATTRibute-CM study of Attruby® (acoramidis) at the European Society of Cardiology (ESC) Congress 2026, highlighting the company’s continued progress in developing therapies for transthyretin amyloid cardiomyopathy (ATTR-CM). The latest findings included analyses from cardiac magnetic resonance imaging (CMR), an open-label extension, and patient-centered outcomes, reinforcing BridgeBio Pharma’s focus on demonstrating the long-term clinical impact of acoramidis in patients with progressive cardiac disease. The company reported that the treatment was associated with evidence of potential improvement in cardiac structure and function, while also showing sustained efficacy and safety through extended follow-up. BridgeBio Pharma’s presentation at ESC 2026 further strengthens the company’s clinical development program for acoramidis and its focus on addressing the underlying progression of ATTR-CM.
BridgeBio Pharma Highlights Long-Term Acoramidis Data
BridgeBio Pharma reported that the CMR substudy of ATTRibute-CM provided evidence that acoramidis may potentially influence the progression of cardiac structural disease over time. The company highlighted serial CMR assessments through Month 42, with analyses evaluating changes in left ventricular systolic function and cardiac structure. In the completer analysis, clinically meaningful improvement in left ventricular systolic function was observed in 54% of acoramidis-treated patients at Month 30, compared with 20% of placebo-treated patients, while 53% of patients continuously receiving acoramidis showed improvement at Month 42. BridgeBio Pharma also reported that 46% of continuously treated patients demonstrated improvement in left ventricular mass index at Month 42. These findings are particularly relevant to the company’s development strategy because they extend the clinical evidence around whether treatment can go beyond slowing ATTR-CM progression and potentially contribute to improved cardiac function.
Company Advances ATTR-CM Development Program
The new ESC findings also support BridgeBio Pharma’s broader clinical development strategy for acoramidis. The company recently dosed the first participant in ASCEND-ATTR, a Phase 3b/4 study designed to further evaluate sustained changes in myocardial structural disease progression, cardiac function and amyloid burden. BridgeBio Pharma also presented extended open-label data evaluating patients with variant ATTR-CM, including individuals carrying the p.Val142Ile variant. Through Month 54, the company reported continued treatment benefits across variant subgroups, together with sustained increases in serum transthyretin and attenuation of NT-proBNP increases. Acoramidis remained well tolerated during the extended follow-up, with no new safety signals reported, supporting the company’s ongoing efforts to establish the long-term profile of its commercialized ATTR-CM therapy.
Advertisement
BridgeBio Pharma Expands Evidence Around Patient Outcomes
Beyond cardiac imaging and long-term follow-up, BridgeBio Pharma highlighted additional analyses examining hospitalization burden and health-related quality of life among patients receiving acoramidis. A post-hoc analysis assessed days lost to death and cardiovascular-related hospitalization, showing that acoramidis-treated patients preserved more time alive and outside the hospital compared with placebo. The company reported an estimated 38-day advantage over 30 months, with the observed difference reaching 65 additional days alive and out of hospital over three years. Additional analyses presented at ESC 2026 evaluated health-related quality of life using EQ-5D-5L and Kansas City Cardiomyopathy Questionnaire measures, with benefits reported across both wild-type and variant ATTR-CM populations. BridgeBio Pharma also showcased its collaboration with Yale’s Cardiovascular Data Science Lab, including AI-based ECG and digital registry approaches aimed at improving ATTR-CM detection, disease monitoring and risk assessment. Together, the presentations demonstrate the company’s expanding strategy around acoramidis, combining therapeutic development with new approaches for identifying and monitoring patients with ATTR-CM.
Source:BridgeBio Pharma, press relese
